Clinical Trials Browser

Phase 1/2 × silmitasertib × 1 year × Clear all

NCT06541262 2026-03-02

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Phase 1/2 Recruiting

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT03904862 2025-10-30

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Phase 1/2 Terminated

Microphthalmia, Isolated, with Coloboma 5, Medulloblastoma